Suivi thérapeutique pharmacologique de l’olanzapine
作者： Zoubir Djerada , Georges Brousse , Philippe Niel , Pierre-Michel Llorca , Alain Eschalier
关键词:
摘要: Resume L’olanzapine, antipsychotique de deuxieme generation, est utilisee pour traiter les schizophrenies ainsi que troubles bipolaires. Son suivi therapeutique pharmacologique (STP) assez couramment realise. L’olanzapine largement absorbee par voie orale (biodisponibilite 85 %) et presente un pic plasmatique se produisant entre 4 et 6 heures apres la prise orale. Elle fortement metabolisee differentes enzymes hepatiques (dont isoformes CYP1A2 et CYP2D6) en grand nombre metabolites inactifs sa demi-vie d’elimination comprise 21 et 60 heures. Une zone precise, ni taux seuil n’ont pu faire l’objet d’un consensus, mais forte variabilite intra- interindividuelle, l’existence d’etudes semblant indiquer une correlation concentrations circulantes d’olanzapine survenue d’echappements therapeutiques ou phenomenes toxiques semblent justifier le STP cette molecule. Compte tenu ces donnees, l’interet du a ete evalue, molecule a : recommande avec 20 μg/L 80 μg/L.
em-consulte.com参考文章(37)
Robert R Conley, Deanna L Kelly, Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacology Bulletin. ,vol. 40, pp. 77- 97 ,(2007)
Michael D. Robertson, Matthew M. McMullin, Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic? Journal of Forensic Sciences. ,vol. 45, pp. 418- 421 ,(2000) , 10.1520/JFS14697J
J Catlow, B J Ring, S A Wrighton, S P Swanson, T J Lindsay, M A Hamman, T Gillespie, B J Cerimele, L K Roskos, Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics. ,vol. 276, pp. 658- 666 ,(1996)
Zhiling Zhou, Xin Li, Kunyan Li, Zhihong Xie, Zeneng Cheng, Wenxin Peng, Feng Wang, Ronghua Zhu, Huande Li, Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography B. ,vol. 802, pp. 257- 262 ,(2004) , 10.1016/J.JCHROMB.2003.11.037
Ole V. Olesen, Kristian Linnet, Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Therapeutic Drug Monitoring. ,vol. 21, pp. 87- 90 ,(1999) , 10.1097/00007691-199902000-00013
Paul J. Perry, Todd Sanger, Charles Beasley, Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. Journal of Clinical Psychopharmacology. ,vol. 17, pp. 472- 477 ,(1997) , 10.1097/00004714-199712000-00006
Ulrike Weiss, Josef Marksteiner, Georg Kemmler, Alois Saria, Wolfgang Aichhorn, Effects of age and sex on olanzapine plasma concentrations. Journal of Clinical Psychopharmacology. ,vol. 25, pp. 570- 574 ,(2005) , 10.1097/01.JCP.0000185427.08268.DB
Ramakrishna VS Nirogi, Vishwottam N Kandikere, Manoj Shukla, Koteshwara Mudigonda, Santosh Maurya, Ravikumar Boosi, Anjaneyulu Yerramilli, Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. Journal of Pharmaceutical and Biomedical Analysis. ,vol. 41, pp. 935- 942 ,(2006) , 10.1016/J.JPBA.2006.01.040
D.F. Zullino, D. Delessert, C.B. Eap, M. Preisig, P. Baumann, Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. International Clinical Psychopharmacology. ,vol. 17, pp. 141- 143 ,(2002) , 10.1097/00004850-200205000-00008
Paul J. Perry, Tami R. Argo, Ryan M. Carnahan, Brian C. Lund, Timothy L. Holman, Vicki L. Ellingrod, Del Miller, The association of weight gain and olanzapine plasma concentrations. Journal of Clinical Psychopharmacology. ,vol. 25, pp. 250- 254 ,(2005) , 10.1097/01.JCP.0000162800.64378.82